anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Drugs that perturb microtubules are commonly used to treat breast cancers of all subtypes in both early stage and metastatic disease, but they are effective in only approximately 50% of patients. High concentrations of microtubule-targeting agents can elicit mitotic arrest in cell culture models; however, recent evidence from primary and metastatic breast cancers has revealed that these agents only accumulate at intratumoral levels capable of inducing abnormal multipolar mitotic spindles, not mitotic arrest. Although the maintenance of multipolar spindles can generate cytotoxic rates of chromosomal instability (CIN), focusing of aberrant multipolar spindles into normal bipolar spindles can dramatically reduce CIN and confer resistance to microtubule poisons. Here, we showed that inhibition of the mitotic kinesin centromeric-associated protein-E (CENP-E) overcomes resistance caused by focusing multipolar spindles. Clinically relevant microtubule-targeting agents used a mechanistically conserved pathway to induce multipolar spindles without requiring centrosome amplification. Focusing could occur at any point in mitosis, with earlier focusing conferring greater resistance to antimicrotubule agents. CENP-E inhibition increased CIN on focused spindles by generating chromosomes that remained misaligned at spindle poles during anaphase, which substantially increased death in the resulting daughter cells. CENP-E inhibition synergized with diverse, clinically relevant microtubule poisons to potentiate cell death in cell lines and suppress tumor growth in orthotopic tumor models. These results suggest that primary resistance to microtubule-targeting drugs can be overcome by simultaneous inhibition of CENP-E. Significance: The increased incidence of polar chromosomes induced by inhibition of the mitotic kinesin CENP-E exacerbates chromosomal instability, reduces daughter cell viability, and improves sensitivity to microtubule-targeting therapies.
The overall aim of the proposed study is to determine the effectiveness of a 3-month yoga program on increasing compliance and improving weight loss while participating in the Sanford Profile program. The 6-month study includes a 3-month randomized, controlled trial using in-person yoga, a yoga DVD, and a stretching DVD (control group) followed by a 3-month post-intervention follow-up. The study will be conducted to test the hypotheses that both in-person yoga classes and DVD yoga participation will result in 1) greater compliance with the Profile program, 2) greater weight loss during the yoga intervention, and 3) greater weight loss 3 months following completion of the intervention compared to the stretching intervention. Compliance will be investigated using percent of days that dietary intake was entered online and percent of days that online records indicate that the program was followed. Changes in weight will be measured using data transmitted from electronic scales that are provided as part of the Profile program. In order to assess weight change after participation in the intervention we will ask participants to continue weighing themselves daily for 3 months following completion of the intervention regardless of whether they completed the Profile program or not. Participants will complete online questionnaires on behavioral and appetite perceptions related to eating, food intake, stress levels, compliance with diet recommendations given to them by Sanford Profile, and perceived benefits of their intervention. We will use these measures to determine the effect of yoga participation on eating behaviors and stress levels.
The invention discloses an extraction method and application of chroogomphus rutilus polysaccharide with anti-motion sickness effects. The polysaccharide takes chroogomphus rutilus as a raw material, and is prepared by a water extraction and alcohol precipitation method. The chroogomphus rutilus polysaccharide is used for prevention and treatment of motion sickness, and the results show that very good anti-motion sickness effects can be provided when 200mg/kg of chroogomphus rutilus polysaccharide is given to the stomach by behavioral experiments and hormone level tests. The motion sickness symptoms such as visceral discomfort, incontinence, piloerection and tremor can be obviously reduced, and the level of 5-HT in serum can be reduced, and the motilin level is improved; and most importantly, rats are in good spirits, has no low spirits and other side effect symptoms. The 200mg/kg of chroogomphus rutilus polysaccharide is an ideal dose for the polysaccharide anti-motion sickness. The extraction method provides a novel material and a reference dose for further development of novel anti-motion sickness drugs with efficient, non-toxic and non-side effects.
BACKGROUND: As autophony can be accompanied by several conditions, it is important to find co-morbidities. This paper reports a patient with Kennedy's disease (spinobulbar muscular atrophy, an X-linked, hereditary, lower motor neuron disease) having autophony as the first symptom.
CASE REPORT: A 62-year-old male presented to the otorhinolaryngology department with autophony that began 2 years previously and worsened after losing weight 3 months prior to presentation. Otoscopic examination demonstrated inward and outward movement of the tympanic membrane, synchronised with respiration. Although he had no other symptoms, facial twitching was found on physical examination. In the neurology department, lower motor neuron disease, with subtle weakness of the tongue, face and upper limbs, and gynaecomastia, were confirmed. He was diagnosed with Kennedy's disease based on genetic analysis.
CONCLUSION: Autophonia was presumed to be attributed to bulbofacial muscle weakness due to Kennedy's disease, and worsened by recent weight loss. Patients with autophony require a thorough history-taking and complete physical examination to assess the nasopharynx and the integrity of lower cranial function.
Subjects implanted with the remedē system device and randomized to the Control group will receive optimal medical therapy through the 6-month Post-Therapy Initiation Visit. Control group subjects will have the remedē system initiated to deliver transvenous stimulation of the phrenic nerve at the 6-month Post-Therapy Initiation Visit (7 months post device implant).
Brachial plexus block (BPB) is frequently used as the sole anesthetic technique for upper extremity surgery. The choice of technique often depends on the site of surgery because the extent of sensory-motor blockade after a BPB varies with the technique used. The investigator is not aware of any single BPB technique that can consistently produce surgical anesthesia of the whole ipsilateral upper extremity. However, occasionally surgery entails that the whole upper extremity is anesthetized, i.e. from the shoulder to the elbow, or even the forearm, wrist or hands. This clinical challenge has been addressed previously using a combination of BPB techniques. The investigator has recently demonstrated that it is feasible to accurately identify majority of the main components of the brachial plexus above the clavicle, including the three trunks, using ultrasound imaging. Since majority of the innervation of the upper extremity, i.e. shoulder, arm, elbow, forearm, wrist and hand, originates from the three trunks of the brachial plexus, the investigator hypothesized that selectively blocking upper, middle and inferior trunks of the brachial plexus will produce surgical anesthesia of the whole ipsilateral upper extremity, except for the area innervated by the intercostobrachial nerve (T2- medial aspect of the upper arm). In addition, there may be a potential advantage that phrenic nerve can be spared, so this blockade will not affect the respiratory function as it is common to see phrenic nerve palsy after interascalene BPB (100%) and supraclavicular BPB (50-67%). The aim of this study is therefore to assess a novel brachial plexus block technique, the "selective trunk block" (SeTB), and provide preliminary clinical evidence of its effectiveness in producing surgical anesthesia of the whole ipsilateral upper extremity.
The invention relates to the chemical and pharmaceutical industry, and more particularly to the creation of adjuvant therapy drugs for the prophylaxis and treatment of oncological diseases. The technical result is the more effective treatment of oncological diseases. This result is achieved in that a known composition with therapeutic and prophylactic activity, which contains water, sugar and honey, treated by an external source of energy, has added thereto inverted sugar, sodium citrate, formic acid and levulinic acid in the following ratio (g/1 L of water): 1-25 sugar; 1-25 honey; 1-700 inverted sugar; 1-200 sodium citrate; 1-40 formic acid; 1-200 levulinic acid. A method for producing the claimed composition is carried out as follows. The following ingredients: sugar, inverted sugar, sodium citrate, formic acid and levulinic acid are placed into a container in the required amounts, mixed and then dissolved in 1 litre of water under agitation and heating to boiling point. The composition is then cooled to room temperature, and honey is added and mixed well. The mixture is treated for a period of from 1 to 200 seconds with electromagnetic oscillations having a frequency of 10-3000 Hz using a magnetic pulse corrector with a magnetic induction of 3-60 T at the centre of the inductor.
Studies suggest that self-reported seizure diaries suffer from 50% under-reporting on average. It is unknown to what extent this impacts medication management. This study used simulation to predict the seizure outcomes of a large heterogeneous clinic population treated with a standardized algorithm based on self-reported seizures. Using CHOCOLATES, a state-of-the-art realistic seizure diary simulator, 100 000 patients were simulated over 10 years. A standard algorithm for medication management was employed at 3 month intervals for all patients. The impact on true seizure rates, expected seizure rates, and time-to-steady-dose were computed for self-reporting sensitivities 0%-100%. Time-to-steady-dose and medication use mostly did not depend on sensitivity. True seizure rate decreased minimally with increasing self-reporting in a non-linear fashion, with the largest decreases at low sensitivity rates (0%-10%). This study suggests that an extremely wide range of sensitivity will have similar seizure outcomes when patients are clinically treated using an algorithm similar to the one presented. Conversely, patients with sensitivity ≤10% would be expected to benefit (via lower seizure rates) from objective devices that provide even small improvements in seizure sensitivity.
Lower-extremity amputations are a major concern for the current state and future of healthcare, with ischemia contributing significantly to this issue. This is an infrequent but serious complication of vasopressor use. Unfortunately, there is little research existing on the topic and even fewer guidelines on treatment options. Vasopressors are often used to treat life-threatening hypotension. However, ischemic changes associated with vasopressor use often do not present for several days. It is frequently recommended that patients undergo amputation when the first signs of ischemia occur. This approach, however, does not allow for the full process of demarcation, making it difficult to determine which portions of the lower extremity will remain viable. This is a case study of a 37-year-old man who developed severe complications from COVID-19 and was subsequently admitted. Because of a complicated hospital course, he required the use of vasopressor medication that subsequently led to the development of ischemic changes to his bilateral forefeet and hands. Through a prolonged period of demarcation and the collaboration of multiple specialties, the patient was able to salvage each limb and maintain his functionality.
PURPOSE:The titled preparation for administrating endermically a fixed amount of nicotin, suppressing a demand for smoking accompanied by reduction in nicotin level in the body without pain, obtained by setting a nicotin-containing high polymer substance layer having adhesion at normal temperature on a substate. CONSTITUTION:In a tape preparation obtained by setting a high polymer substance layer having adhesivity at normal temperature on a substrate, nicotin is added to the high polymer substance layer. Especially (meth)acrylate high polymer substance is preferable as the high polymer substance with resect to stability, releasability of nicotin and adhesiveness. Endermic administration of nicotin makes approximately constant nicotin concentration for a long period, suppresses a demand for smoking and makes smoking and reduction in smoking possible without psychological and physiological pains. Handling is much simpler than an existing nicotin administration method. Successively application of preparations having much lower nicotine content can surely show effects.
BACKGROUND: Circular RNAs (circRNAs), which are a new type of single-stranded circular RNA, have significant involvement in progression of many diseases, including tumors. Currently, multiple circRNAs have been identified in hepatocellular carcinoma (HCC). Our study aims to investigate the function and mechanism of circDCAF8 in HCC.
METHODS: The expression of circDCAF8 (hsa_circ_0014879) in HCC and para-carcinoma tissue samples was determined using quantitative real-time polymerase chain reaction (qRT-PCR). The biological function of circDCAF8 in HCC was confirmed by experiments conducted both in vitro and in vivo. And the relationship between circDCAF8, miR-217 and NAP1L1 was predicted by database and verified using qRT-PCR, RNA-binding protein immunoprecipitation (RIP) and dual-luciferase reporter assays. Exosomes isolated from HCC cells were utilized to assess the connection of exosomal circDCAF8 with HCC angiogenesis and regorafenib resistance.
RESULTS: CircDCAF8 is upregulated in HCC tissues and cell lines, and is linked to an unfavourable prognosis for HCC patients. Functionally, circDCAF8 was proved to facilitate proliferation, migration, invasion and Epithelial-Mesenchymal Transformation (EMT) in HCC cells. Animal examinations also validated the tumor-promoting characteristics of circDCAF8 on HCC. Besides, exosomal circDCAF8 promoted angiogenesis in HUVECs. Mechanistically, circDCAF8 interacted with miR-217 and NAP1L1 was a downstream protein of miR-217. CircDCAF8 promoted NAP1L1 expression by sponging miR-217. In addition, exosomes may transfer circDCAF8 from regorafenib-resistant HCC cells to sensitive cells, where it would confer a resistant phenotype.
CONCLUSION: CircDCAF8 facilitates HCC proliferation and metastasis via the miR-217/NAP1L1 axis. Meanwhile, circDCAF8 can promote angiogenesis and drive resistance to regorafenib, making it a viable therapeutic target for HCC patients.
Group 1 will begin with active Levocetirizine(LCT) 0.5 mg/ml oral solution for 5-8 days. This arm will then undergo a 3-7 day washout period at which point crossover will occur and placebo will be provided for 5-8 days.
Methods are provided for identifying agents that modulate signaling mediated by transforming growth factor beta (TGF-.beta.) and members of the TGF-.beta.  family, such as bone morphogenic protein (BMP). Such agents may be identified using screens that evaluate candidate agents for the ability to modulate Smad protein degradation. Agents identified as described herein may be used to augment or inhibit signaling mediated by one or more TGF-.beta. family members in a variety of cell types and for therapeutic purposes.
Cinnamon has been shown to delay gastric emptying (GE) of a high-carbohydrate meal and reduce postprandial glycaemia in healthy adults. However, it is dietary fat which is implicated in the etiology and is associated with obesity, type 2 diabetes (T2D) and cardiovascular disease (CVD). We aimed to determine the effect of 3 g cinnamon on GE, postprandial lipemic and glycemic responses, oxidative stress, arterial stiffness, as well as appetite sensations and subsequent food intake following a high-fat (HF) meal.

The effect of acute oral administration of 3 g cinnamon on gastric emptying of a high-fat pancake test meal and subjective appetite sensations by visual analogue scale will be measured for six hours postprandially. During this time course, measurements of postprandial lipemic, glycemic, oxidative stress and arterial stiffness responses will be collected. Subsequently, food intake will be measured using an ad libitum buffet meal. The study will be conducted in a randomized, placebo-controlled, single-blinded manner in 9 healthy subjects.
Provided are a traditional Chinese medicine composition for treating chronic lower limb venous diseases, a decoction thereof, and a formulation thereof. The traditional Chinese medicine composition comprises raw Astragali Radix, Spatholobi Caulis, Atractylodis Macrocephalae Rhizoma, Dendrobii Caulis, Angelicae Sinensis Radix, Centellae Herba, Chuanxiong Rhizoma, Liquidambaris Fructus, Lycopodii Herba, Anemones Raddeanae Rhizoma, Cimicifugae Rhizoma, and Bupleur Radix. The decoction is prepared by decocting the traditional Chinese medicine composition. The formulation is prepared from an extract prepared by mixing the traditional Chinese medicine composition, decocting in water, filtering, and concentrating, and a pharmaceutically acceptable excipient. The traditional Chinese medicine composition and the formulation thereof can raise yang and invigorate veins, have comprehensive therapeutic effects on diseases such as edema, pain, pruritus, and sore and ulcers in various stages of disease development in patients suffering from chronic lower limb venous diseases, and can ameliorate the symptoms, thus preventing the diseases from progress or onset. Related formulations of the traditional Chinese medicine composition feature ease to prepare, diversity in form, and cost-efficiency, and can meet the treatment requirements of different patients.
Pneumocystis pneumonia is a severe fungal disease threatening immunosuppressed subjects such as patients suffering from AIDS, oncohematological diseases or solid organ transplanted patients. The disease is characterized by an important inflammation in the infected lungs which is mainly responsible for lungs lesions. Despite an adequate treatment introduction, mortality is still around 20% which can not be explained by a treatment resistance. Specialized proresolving mediators (SPM), including lipoxins, maresins, protectins and resolvins, are newly described molecules implicated in the active process of inflammation resolution. The investigators hypothesis in this study is that high levels of SPM could be predictive of a good resolution of the harmful inflammation, thus a good evolution of the disease, in adequate pneumocystosis therapy conditions. On the contrary, low levels of SPM could be predictive of an unfavourable outcome despite a treatment targeting Pneumocystis jirovecii
In the base study (P05788, 38833, NCT00702351), participants were pre-treated with daily SC injections of 0.1 mg triptorelin started between Day 21 and 24 of the menstrual cycle (mid luteal phase). After suppression of endogenous LH and FSH was confirmed by E2 and P measurements, a single dose of corifollitropin alpha 150 μg was administered in participants weighing \>= 50 kg. From stimulation Day 8 onwards, treatment was continued with daily SC of recFSH injections (maximally 200 IU) up to and including the day of administration of hCG. No study medications were administered in the present P05783 study (38834, NCT00702520).
Enhanced Usual Care (EUC) will involve delivery of monthly newsletters (6 newsletters) on the topics of post-lung transplant management, including food safety, environmental health, flu, mental health, etc. and the provision of a self-monitoring device.
Lung cancer is the rapidest increased type of cancer in China with over 5 times incidence rate increase during the past 30 years . It is the leading cause of death of cancer in man and 2nd in women. With the development of gefitinib and erlotinib, EGFR-TKI (epidermal growth factor receptor -tyrosine kinase inhibitor) is the most successful novel drugs developed for the treatment of these patients in recent years, especially for NSCLC patients in Asia including China. Icotinib is a novel EGFR-TKI developed by a group of Chinese scientists and clinician. It appears to be at least as good as gefitinib in terms of efficacy and better in terms of safety in phase I/II trials. In this study, a randomized, double-blind, gefitinib as control, multi-center phase III trial was designed to evaluate the safety and efficacy of icotinib in the treatment of advanced NSCLC patients after failure of 1 or 2 chemotherapy. PFS (progress free survival) is the primary end-point with OS (overall survival), ORR (objective response), TTP (time to progress), HRQOL and safety as the secondary end-point. A total of 400 patients will be recruited. EGFR and K-ras gene mutational analysis as well as a population PK study have also been proposed.
An expandable microcapsule comprises a core layer including 300 parts by weight of a foaming agent, 250 parts by weight of a polymer absorbent material and 60 parts by weight of a core layer lubricant, wherein the foaming agent has the property of reacting with water to generate gas; and a coating layer for coating the surface of the core layer to form a granular structure, wherein the coating layer contains 10% to 40% by weight of edible water absorbing gel, 5% to 40% functional healthy food additive, 2% to 30% emulsifier, 4% to 15% coating layer lubricant and 5% to 40% film coated composition. The film coated composition is resistant to gastric acid decomposition and can only be decomposed in the intestinal tract. The foaming agent includes 100 to 300 parts by weight of acidic compound and 130 to 410 parts by weight of basic compound. The acidic compound includes at least one of citric acid and tartaric acid. The basic compound includes at least one of sodium carbonate, sodium bicarbonate, potassium carbonate and potassium bicarbonate. The polymer absorbent material is sodium polyacrylate. The polymer absorbent material is ultra-finely pulverized to more than 300 mesh and dried for 5 hours at 40°C to 80°C. The core layer lubricant includes 20 to 60 parts by weight of internal lubricant and 2 to 6 parts by weight of external lubricant. The internal lubricant includes one of polyethylene glycol 4000 and polyethylene glycol 6000 or a combination thereof. The external lubricant includes magnesium stearate, talc or one of L-leucine and DL-leucine or any combination thereof. The foaming agent, the polymer absorbent material and the internal lubricant are mixed, added by 240 parts by weight of the soft material made of absolute ethanol, and dried at 40°C to 80°C after sieving and granulating so that the moisture content of the mixture particles is less than 3%. Thereafter, the external lubricant is added and mixed to obtain the core layer.